AbCellera prices $200 million share offering at $9.75 per common share
AbCellera priced an underwritten public offering of 17,435,897 common shares at $9.75 per share, plus pre-funded warrants for up to 3,076,926 shares, with closing expected on or about August 14, 2026. The company estimates net proceeds of about $187.0 million and plans to use them to fund its internal pipeline, including lead clinical program ABCL635, and for working capital. The new shares will add to the existing share count, which dilutes current shareholders' ownership.
Key points
- Priced 17,435,897 common shares at $9.75 per share, and pre-funded warrants for up to 3,076,926 shares at $9.74999 each
- Gross proceeds expected to be about $200.0 million; estimated net proceeds about $187.0 million after underwriting discounts, commissions and offering expenses
- Proceeds to fund research, development and clinical advancement of the internal pipeline, including ABCL635, and for working capital and general corporate purposes
- Closing expected on or about August 14, 2026; the company and its executive officers and directors agreed to a 60-day restriction on share sales, subject to exceptions
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.